What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The pivotal PATHFNDR-1 trial demonstrated that 83.3% of patients maintained IGF-I levels on paltusotine compared to 3.6% on placebo, indicating strong efficacy in maintaining biochemical control. However, the lack of direct comparison against standard injectable therapies limits the strength of the evidence, as it only shows superiority over placebo rather than active comparators.
Does the economic case hold at the expected price? — Cost effectiveness
There is no public cost-utility analysis or budget impact model available for paltusotine, which is a significant gap for HTA purposes. The absence of economic evidence makes it difficult to assess its cost-effectiveness, leading to a classification of non-cost-effective.
Is there quality-of-life evidence payers weigh? — Quality of life
While paltusotine showed some improvements in HRQoL measures like EQ-5D-5L and AcroQoL, the results were not statistically significant in the pivotal trial. The evidence for patient-reported outcomes is present but insufficient for robust reimbursement modeling, indicating a lack of clear benefit in overall quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of paltusotine is consistent with the somatostatin-receptor-ligand class, with common adverse events being manageable and no severe events reported in the pivotal trials. This indicates a favorable safety profile compared to placebo, although long-term safety data are still maturing.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal trial used a placebo comparator after withdrawal from injectable therapies, which does not align with real-world practice where continued injectable therapy is the standard. This limits the relevance of the evidence for payers who expect active comparator data.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in PATHFNDR-1 is reasonably representative of adults controlled on injectable therapies, but exclusions limit applicability to more complex cases. The inclusion of both medically untreated and washout patients in PATHFNDR-2 enhances generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Paltusotine can be integrated into existing care pathways with manageable adjustments, primarily due to its oral administration. However, monitoring requirements remain significant, indicating that while integration is feasible, it is not without challenges.
Are the wider system costs understood? — Resource Use and Cost Implications
No public analysis quantifying the resource use or budget impact of paltusotine has been identified, leading to uncertainty about its economic implications. This lack of data raises concerns about its affordability and sustainability in healthcare systems.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two randomized, double-blind phase 3 trials, which are robust by rare-disease standards. However, the reliance on open-label extensions for long-term data introduces some uncertainty regarding the durability of treatment effects.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the clinical evidence is strong, there are significant uncertainties regarding real-world effectiveness and economic modeling. The absence of robust economic data and real-world studies limits the ability to fully assess broader impacts and equity considerations.
